MOTS-csafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for MOTS-c as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. MOTS-c is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

MOTS-c safety data come primarily from pre-clinical work and limited early-phase exploratory clinical studies. The pre-clinical safety record across rodent metabolic and exercise studies has been favourable: subcutaneous doses of 0.1-15 mg/kg over weeks-to-months have produced no overt toxicity, no significant changes in routine haematology or hepatic enzymes, and no organ-specific lesions in standard histopathology. As an endogenous peptide, MOTS-c is unlikely to produce significant immunogenicity at typical research doses, though anti-MOTS-c antibodies have been detected in some chronic-dosing studies. The theoretical safety considerations centre on the AMPK pathway's broad role in cellular energy homeostasis. AMPK activation drives catabolic processes (fatty acid oxidation, autophagy, glucose disposal) while inhibiting anabolic processes (lipogenesis, protein synthesis). Sustained or excessive AMPK activation could theoretically impair growth, anabolic recovery from exercise, or tissue regeneration — though the pre-clinical data have not identified clinically significant adverse effects at research doses. The folate-cycle component of MOTS-c mechanism raises theoretical considerations about methylation and one-carbon metabolism. The folate-cycle competition with methotrexate suggests that MOTS-c could theoretically affect cellular folate handling and downstream methylation reactions, with potential implications for DNA repair, neurotransmitter synthesis, and other folate-dependent processes. The pre-clinical work has not identified clinically significant methylation perturbations at research doses, but human chronic dosing has not been adequately characterised. Mild injection-site reactions are documented at higher doses. No serious adverse events have been reported in any published MOTS-c research. The acute safety profile in research animals is favourable; chronic and human safety remains incompletely characterised. Research protocols should consider that MOTS-c is an endogenous peptide whose plasma concentration declines with age and metabolic disease — administration is essentially restoring an endogenous regulator rather than introducing a novel pharmacological agent, which is a different safety framing than for synthetic non-endogenous compounds.

UK regulatory status

MOTS-c is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Supply or administration of MOTS-c to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. Research-grade material for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. MOTS-c is not currently on the WADA Prohibited List as a specifically-named substance. However, WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and S0 category (Non-Approved Substances) could be argued to apply depending on WADA interpretation. The exercise-performance research relevance of MOTS-c — improved treadmill endurance and physical activity in aged mice — makes it a substance athletes should treat conservatively pending clearer WADA guidance. Athletes should consult the current annual WADA Prohibited List and seek guidance from their national anti-doping body before any administration. For animal research under ASPA, MOTS-c work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. MOTS-c is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full MOTS-c research context including mechanism, study citations, and references, see the main MOTS-c research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.